The novel, orally available and peripherally restricted selective cannabinoid CB2 receptor agonist LEI‐101 prevents cisplatin‐induced nephrotoxicity
British Journal of Pharmacology2015Vol. 173(3), pp. 446–458
Citations Over TimeTop 10% of 2015 papers
Partha Mukhopadhyay, Marc P. Baggelaar, Katalin Erdélyi, Zongxian Cao, Reşat Çınar, Filomena Fezza, Bogna Ignatowska‐Janlowska, Jenny L. Wilkerson, Noortje van Gils, Thomas Hansen, Marc D. Ruben, Marjolein Soethoudt, Laura H. Heitman, George Kunos, Mauro Maccarrone, Aron H. Lichtman, Pál Pacher, Mario van der Stelt
Abstract
These results indicate that LEI-101 is a selective, largely peripherally restricted, orally available CB2 receptor agonist with therapeutic potential in diseases that are associated with inflammation and/or oxidative stress, including kidney disease.
Related Papers
- → CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents(2004)241 cited
- → Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes(2002)101 cited
- → Distribution of cannabinoid receptors in rat brain determined with aminoalkylindoles(1992)141 cited
- → Cannabinoid–improgan cross-tolerance: Improgan is a cannabinomimetic analgesic lacking affinity at the cannabinoid CB1 receptor(2006)9 cited
- → Cannabinoid Ligand-Receptor Signaling During Early Pregnancy in the Mouse(1999)3 cited